РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ ТЕНЕКТЕПЛАЗЫ ПРИ МАССИВНОЙ ТРОМБОЭМБОЛИИ ЛЕГОЧНОЙ АРТЕРИИ. КЛИНИЧЕСКИЙ СЛУЧАЙ
https://doi.org/10.20996/1819-6446-2011-7-1-42-48
Аннотация
Тромбоэмболия легочной артерии (ТЭЛА) — это жизнеугрожающее состояние, которое может привести к летальному исходу в любом возрасте. Наиболее значимым изменением в представлениях о ТЭЛА за последние десятилетия стало понимание того, что это не самостоятельное заболевание, а осложнение венозной тромбоэмболии. В литературе высказывают противоречивое мнение о возможности применения активатора тканевого плазминогена — тенектеплазы. Описывают клинический случай применения тенектеплазы у 42-летней женщины с острой массивной ТЭЛА и его результаты. В описанном случае ТЭЛА наблюдалась одновременно с диабетическим кетоацидозом. У пациентки, госпитализированной в течение 24 ч после появления симптомов, наблюдали полное разрушение тромба по данным компьютерной ангиографии легких. Это один из первых случаев эффективного применения тенектеплазы у пациентов с массивной ТЭЛА и диабетическим кетоацидозом.
Об авторах
Р. Раджан
Институт медицинских исследований штата Керала. Индия, Тривандрум
Индия
Индия
врач-исследователь, старший аспирант отделения кардиологии
Р. Натараджан
Институт медицинских исследований штата Керала. Индия, Тривандрум
Индия
Индия
кардиолог-интервенционист, старший консультант
Г. Виджейрагхаван
Институт медицинских исследований штата Керала. Индия, Тривандрум
Индия
Индия
руководитель отделения кардиологии, заместитель директора
Список литературы
1. Miller E.J., Marques M.B., Simmons G.T. Etiology of Pulmonary Thromboembolism in the Absence of Commonly Recognized Risk Factors. Am J Forensic Med Pathol 2003 Dec;24(4):329-33.
2. Shujaat A., Shapiro J.M. Massive pulmonary embolism in diabetic ketoacidosis and non-ketotic hyperosmolar state: case series and review of the literature. Clin Intensive Care 2004; 15(2/3): 73-77.
3. Nordt T.K., Bode C. Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches. Semin Thromb Hemost 2000; 26(5):495-501.
4. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15(1): 44-54.
5. Ceriello A., Giugliano D., Quatraro A. et al. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990; 33(3):163-167.
6. Hansson P.O., Welin L., Tibblin G., Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med 1997;157(15):1665-1670.
7. Worsley D.F., Alavi A. Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. J Nucl Med 1995;36(12):2380-7.
8. Refino C.J., Paoni N.F., Keyt B.A. et al. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993;70(2):313-9.
9. Quiroz R., Kucher N., Zou K.H. et al. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism. JAMA 2005;293(16):2012-17.
10. Perrier A., Bounameaux H. Accuracy or outcome in suspected pulmonary embolism. N Engl J Med 2006; 354(22): 2383-85.
11. Goldhaber S.Z. Pulmonary embolism. N Engl J Med 1998;339(2):93-104.
12. Stein P.D., Hull R.D., Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med 1994;121(5):313-7.
13. Keyt B.A., Paoni N.F., Refino C.J. et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994;91(9):3670-4.
14. Collen D., Stassen J.M., Yasuda T. et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 1994;72(1):98-104.
15. Benedict C.R., Refino C.J., Keyt B.A. et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92(10):3032-40.
16. Petrauskiene V., Falk M., Waernbaum I. et al. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005; 48(5):1017-1021.
17. Büyükasik Y., Ileri N.S., Haznedaroglu I.C. et al. Enhanced subclinical coagulation activation during diabetic ketoacidosis. Diabetes Care 1998; 21(5): 868-870
18. Ileri N.S., Büyükasik Y., Karaahmetoglu S. et al. Evaluation of the haemostatic system during ketoacidotic deterioration of diabetes mellitus. Haemostasis 1999; 29(6):318-325
19. Quigley R.L., Curran R.D., Stagl R.D., Alexander J.C. Jr. Management of massive pulmonary thromboembolism complicating diabetic ketoacidosis. Ann Thorac Surg 1994; 57(5):1322-1324.
20. Kasper W., Konstantinides S., Geibel A. et al. Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism; results of a multicenter registry (MAP-PET). J Am Coll Cardiol 1997; 30(5):1165-71.
21. Goldhaber S.Z., Visani L. et al. Acute pulmonary embolism: clinical outcomes in the international Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353(9162):1386-9.
22. Newman D.H., Greenwalk I., Callaway C.W. Cardiac arrest and the role of thrombolytic agents. Ann Emerg Med 2000; 35(5):472-80.
23. Konstantinides S., Geibel A., Olschewski M. et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism. Circulation 1997; 96(3):882-8.
24. Sharma G.V.R.K., Folland E.D., McIntyre K.M. et al. Long-term hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease (abstract). JACC 1990:65A.
25. Ribeiro A., Lindmarker P., Johnsson H. et al. Pulmonary embolism; one-year follow up with echocardiography Doppler and five-year survival analysis. Circulation 1999; 99(10): 1325-30.
26. Konstaneinides S., Geibel A., Olschewski M. et al. Impact of thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism; Results of multicentre registry. Circulation 1997;96(3):882-888.
27. Urokinase pulmonary embolism trial: Phase I Results. JAMA 1970;214(12):2163-2172.
28. Bottiger B.W., Bode C., Kern S. et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001;357(9268):1583-5.
29. Lederer W., Lichtenberger C., Pechlaner C. et al. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. Resuscitation 2001;50(1):71-6.
30. Ruiz-Bailen M., Aguayo de Hoyos E., Serrano-Córcoles M.C. et al. Efficacy of thrombolysis in patients with acute myocardial infarction requiring cardiopulmonary resuscitation. Intensive Care Med 2001;27(6):1050-7.
31. Voipio V., Kuisma M., Alaspää A. et al. Thrombolytic treatment of acute myocardial infarction after out-of-hospital cardiac arrest. Resuscitation 2001;49(3):251-8.
32. Bozeman W.P., Kleiner D.M., Ferguson K.L. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. Resuscitation 2006;69(3):399-406.
33. Fengler B.T., Brady W.J. Fibrinolytic therapy in pulmonary embolism: an evidence-based treatment algorithm. Am J Emerg Med 2009;27(1):84-95.
34. Goldhaber S.Z. Pulmonary embolism thrombolysis. Circulation 1997;96(3):716-718.
35. Kline J.A., Hernandez-Nino J., Jones A.E. Tenecteplase to treat pulmonary embolism in the emergency department. J Thromb Thrombolysis 2007;23(2):101–105.
36. Meyer G. The PEITHO study: for a clarification of the indications for the fibrinolytic treatment of pulmonary embolism. Rev Pneumol Clin 2008;64(6):326-7.
37. Sphr F., Arntz H.R., Bluhmki E. et al. International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. Eur J Clin Invest 2005; 35(5):315-23.
38. Sze D.Y., Carey M.B., Razavi M.K. Treatment of massive pulmonary embolus with catheter-directed tenecteplase. J Vasc Interv Radiol 2001; 12(12):1456–1457.
39. The urokinase pulmonary embolism trial. A notional cooperative study. Circulation 1973;47(2 Suppl): II1-108.
40. Dalla Volta S., Palla A., Santolicandro A. et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Ital-ian multicentre study 2. J Am Coll Cardiol 1992;20(3):520-526.
41. Levine M., Hirish J., Weitz J. et al. A randomized trial of single bolus dosage regimen of recombinant tissue plaminogen activator in patients with acute pulmonary embolism. Chest 1990;98(6):1473-1479.
42. Meyer G., Sors H., Charbonnier B. et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multi-center double-blind trial. The European Cooperative study Group for Pulmonary Embolism. J Am Coll Cardiol 1992;19(2):239-245.
43. Goldhaber S.Z., Kessler C.M., Heit J. et al. Randomised controlled trial of recombinant tissue plasminogen activatr versus pulmonary embolism. Lancet 1988;2(8606):293-398.
44. Sors H., Pacouret G., Azarian R. et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multi center trial. Chest 1994;106(3):712-717.
45. Verstraete M., Miller G.A., Bounameaux H. et al. Intravenous and intra pulmonary recombinant tissue type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77(2):353-360.
46. Konstantinides S., Geibel A., Heusel G. et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347(15):1143-1150.
47. Goldhaber S.Z., Haire W.D., Feldstein M.L. et al. Alteplase versus heparin in acute pulmonary embolism; randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341(8844):507-511.
48. Stein P.D., Hull R.D., Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of non-invasive management trial. Ann Intern Med 1994;121(5):313-7.
49. Torbicki A., Perrier A., Konstantinides S. et al. Guidelines on diagnosis and management of Acute Pulmonary Embolism: the Task Force for the diagnosis and management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29(18):2276-2315.
Рецензия
Для цитирования:
Раджан Р., Натараджан Р., Виджейрагхаван Г. РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ ТЕНЕКТЕПЛАЗЫ ПРИ МАССИВНОЙ ТРОМБОЭМБОЛИИ ЛЕГОЧНОЙ АРТЕРИИ. КЛИНИЧЕСКИЙ СЛУЧАЙ. Рациональная Фармакотерапия в Кардиологии. 2011;7(1):42-48. https://doi.org/10.20996/1819-6446-2011-7-1-42-48
For citation:
Rajan R., Natarajan R., Vijayaraghavan G. RESULTS OF TENEKTEPLASE USE IN MASSIVE PULMONARY THROMBOEMBOLISM. CLINICAL CASE. Rational Pharmacotherapy in Cardiology. 2011;7(1):42-48. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-1-42-48
Просмотров:
664
Послать статью по эл. почте 